Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
Extrapolating from the Adriatic trial.
Related Questions
Do you perform EBUS-TBNA for staging in patients with biopsy proven malignant lung nodules with no lymphadenopathy on CT chest and PET scan?
How would you approach an in-field recurrence after lung SBRT for a T1 NSCLC in a patient with poor underlying lung function?
How would you approach SBRT in a pacemaker-dependent elderly patient with Stage I NSCLC whose SBRT plan Dmax exceeds the pacemaker tolerance?
Do you use any drugs prophylactically to reduce the risk of radiation pneumonitis in lung SBRT?
When contouring locally advanced NSCLC, how do you define your ITV if your iGTV overlaps with an OAR?
How do you treat Stage IIIC T4N3 NSCLC?
How would you post-operatively manage a peripheral stage I small cell lung carcinoma s/p upfront wedge resection with an R1 microscopic positive margin along the staple line and visceral pleural invasion?
What CTV expansions do you use for NSCLC with conventional chemoradiation and do you do different expansions based on specific histologies?
Would you offer SBRT for a lung lesion adjacent to the heart in a patient receiving bevacizumab?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?